Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Novo Nordisk ( ($NVO) ) has shared an announcement. On 2 February 2026, Novo Nordisk reported headline phase 3 results from its REIMAGINE 2 trial s...

Novo Nordisk’s CagriSema Tops Semaglutide in Major Phase 3 Diabetes Trial

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk, with a price target of DKK390.00. According to TipRan...

UBS Sticks to Its Hold Rating for Novo Nordisk (0QIU)

In a report released on January 30, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk, with a price target of DKK430.00. The ...

Kepler Capital  Sticks to Its Buy Rating for Novo Nordisk (0QIU)

U.S. stocks ended the week lower as pressure from rates and commodities weighed on risk appetite. The Dow Jones Industrial Average (DJIA) fell 0.36...

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

Novo Nordisk ( ($NVO) ) has fallen by -7.11%. Read on to learn why. Novo Nordisk shares slipped 7.11% over the past week as investors weighed the c...

Novo Nordisk Slides as Weight-Loss Drug War Escalates

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk today and set a price target of DKK350.00. According to TipRanks, Vosser...

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

The pharma giants are fighting for market share. 


Novo Nordisk Is Spending Twice as Much as Eli Lilly (LLY) on Weight-Loss Drug Ads

The new campaign comes as competition heats up. 


Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’

In a report released on January 23, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk, with a price target of DKK430.00. The ...

Kepler Capital  Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Danish drugmaker Novo Nordisk’s ($NVO) shares rose about 3% as data showed that over 18,000 prescriptions were issued in the first week of the laun...

Novo Nordisk Stock (NVO) Gains on Obesity Pill Demand as Goldman Flags Earnings Upside

Novo Nordisk’s ($NVO) new weight-loss pill recorded 18,410 prescriptions in the U.S. during its first full week of availability, according to marke...

Novo Nordisk’s Wegovy Pill Records Nearly 20,000 Prescriptions in First Week

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk Tests New CagriSema Injection Devices in Type 2 Diabetes Stud...

Novo Nordisk’s Next Move in Diabetes: New CagriSema Injection Devices Enter Phase 2

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk is preparing a new Phase 3 trial that compares two injection ...

Novo Nordisk Advances CagriSema Device Study, Reinforcing Its Obesity Pipeline

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. CagriSema Trial Update: What Novo Nordisk’s Next Diabetes Combo Could Mean...

Novo Nordisk’s CagriSema Trial Completes: What the Next-Gen Diabetes Combo Could Mean for NVO Investors

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk today and set a price target of DKK436.00. Quigley covers the Healthcar...

Goldman Sachs Remains a Buy on Novo Nordisk (0QIU)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novo Nordisk (NVO – Research Report) and HCA Healthcare (HCA – Re...

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and HCA Healthcare (HCA)

Kepler Capital analyst David Evans maintained a Buy rating on Novo Nordisk on January 19 and set a price target of DKK430.00. The company’s shares ...

Kepler Capital  Keeps Their Buy Rating on Novo Nordisk (0QIU)

Swiss drugmaker Novartis ($NVS) has said it expects to reduce its U.S. tariff exposure to a minimum by halfway through this year due to its agreeme...

Novartis Stock (NVS) Holds on Upbeat View of Tariff Exposure amid U.S.-EU Tension

UBS analyst Matthew Weston maintained a Hold rating on Novo Nordisk today and set a price target of DKK390.00. According to TipRanks, Weston is a 4...

Novo Nordisk (0QIU) Receives a Hold from UBS

A new U.S.-EU trade war is brewing and could leave several European stocks across pharmaceutical, auto, and fashion possibly exposed. What’s Happen...

These European Stocks Could Be in the Firing Line in Trump’s Greenland Tariff War

U.S. stocks finished the week essentially flat as a semiconductor-led bid was offset by softer bank performance and a steady drumbeat of policy hea...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 18

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk today and set a price target of DKK475.00. Papadakis covers the He...

Deutsche Bank  Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

In a report released today, Luisa Hector from Berenberg Bank maintained a Buy rating on Novo Nordisk, with a price target of DKK415.00. According t...

Novo Nordisk (0QIU) Gets a Buy from Berenberg Bank

Rival Novo Nordisk is already selling its obesity pill in America. 


Eli Lilly Stock (LLY) Falls 5% After FDA Delays Decision on Weight-Loss Pill

Wall Street has labeled the airline industry as a surprising winner from the growing use of weight-loss drugs. More specifically, with the first GL...

Why GLP-1 Weight-Loss Pills Might Be Great News for Airlines

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk has launched AMAZE 1, a Phase 3 trial titled ...

Novo Nordisk’s AMAZE 1 Obesity Trial Signals Next Wave in Weight-Loss Pipeline

The brokerage highlights an impressive pipeline of new medications. 


BMO Capital Markets Pounds the Table on Eli Lilly Stock (LLY)

Danish pharmaceutical giant Novo Nordisk ($NVO) is open to big or small deals to bolster its obesity drug portfolio. In an interview with Bloomberg...

Novo Nordisk (NVO) Is Open to M&A to Bolster Obesity Drug Portfolio

Novo Nordisk ($NVO) CEO Mike Doustdar said that as many as 1.5 million people in the U.S. may now be using compounded versions of popular GLP-1 wei...

Novo Nordisk (NVO) Rethinks Pricing as Compounded GLP-1 Drugs Gain Ground

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Novo Nordisk today and set a price target of DKK400.00. Hector covers the Healthcare...

The obesity drug market is red-hot right now. 


Amazon (AMZN) Begins Selling Novo Nordisk’s Weight-Loss Pill

Danish pharma giant Novo Nordisk’s ($NVO) shares bubbled with life on Friday afternoon as retail giant Amazon’s ($AMZN) digital pharmacy kicked off...

Novo Nordisk Stock (NVO) Jumps as Amazon Begins Selling Obesity Pill

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk Targets Youth Diabetes With New CagriSema Trial The study, of...

Novo Nordisk Expands CagriSema Push Into Youth Diabetes: Early Trial Update for Investors

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is running a clinical study called “An Invest...

Novo Nordisk’s CagriSema Appetite Study Adds Depth to Its Obesity Pipeline

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Buy rating on Novo Nordisk, with a price target of $62.00. The compa...

Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (NVO)

The company’s drug pipeline is underappreciated, argues the bank. 


Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup

Barclays analyst Yihan Li maintained a Hold rating on Novo Nordisk today and set a price target of DKK360.00. According to TipRanks, Li is ranked #...

Novo Nordisk (0QIU) Receives a Hold from Barclays

The race for obesity-drug market share was one key highlight for Big Pharma in 2025. However, data shows the Big Pharma rally seen in 2025 is more ...

LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze

Lilly’s new weight-loss pill is expected this summer. 


Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

The weight-loss war is moving from the needle to the medicine cabinet as Novo Nordisk ($NVO) officially launches its daily Wegovy pill in the Unite...

Current Quarter	$0.89	Next Quarter	$0.47
Current Year	$3.58	Next Year	$3.29
QoQ Growth	-47.2%	YoY Growth	-8.1%
3Y EPS CAGR	+29.7%	Target Price	$57.16
Consensus	Buy	Upside	-3.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVO	$58.93	-0.84%	16.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVO	$58.93	-0.8%	16.61M
3
4
5
6

NVO

NVO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Novo Nordisk A/S Data in Excel

Get Novo Nordisk A/S Data in Excel